Focus On Health Care

Pharma Pipelines, by the Numbers


Europe’s pharma pipeline disclosure is more detailed than in the U.S., where drugs in phase I trials are not always disclosed. This means counting the total number of drugs in development is more accurate in Europe.

Gambrell is a contributing graphics editor for Bloomberg Businessweek.

The Good Business Issue
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus